Skip navigation

U.S. review extended on broader use of Merck vaccine

U.S. regulators have extended their review of Merck & Co's application to expand the use of its cervical cancer vaccine to an older group of women, and are now expected to act by year end, the drugmaker said on Wednesday. Full story

Merck posts $3.4 billion third-quarter profit

Drugmaker Merck & Co. on Thursday posted a bigger profit in the third quarter due to slightly higher sales and a huge gain from selling a business. Full story

CDC: 1 in 3 teen girls got cervical cancer vaccine

One in three teenage girls have rolled up their sleeves for a vaccine against cervical cancer, but vaccination rates vary dramatically between states, according to a new federal report. Full story

FDA backs new cervical cancer vaccine Cervarix

Federal health officials favor approving GlaxoSmithKline's long-delayed vaccine Cervarix to prevent the leading cause of cervical cancer in U.S. women. Full story

New shot blocks cervical cancer virus, FDA says

A vaccine from GlaxoSmithKline blocks the virus that causes most cases of cervical cancer, the U.S. Food and Drug Administration said Friday. Full story

HPV vaccine a suggestion, not mandate, in U.S.

Only Virginia and the District of Columbia have moved toward requiring sixth-grade girls to get vaccinated for a potentially cancerous sexually transmitted disease. Full story

Sponsored Links


Have questions about the Gardasil vaccine?

advertisement | ad info